Minor histocompatibility antigens as targets of cellular immunotherapy in leukaemia

Best Practice and Research: Clinical Haematology

Volumn 17, Issue 3 SPEC.ISS., 2004, Pages 415-425

  Falkenburg, J H Frederik ^a   Willemze, Roel ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Allogeneic stem cell transplantation; Graft vs. leukaemia; Minor histocompatibility antigens

Indexed keywords

HLA ANTIGEN; HY ANTIGEN; MINOR HISTOCOMPATIBILITY ANTIGEN; T LYMPHOCYTE RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CHRONIC MYELOID LEUKEMIA; CYTOMEGALOVIRUS INFECTION; EPSTEIN BARR VIRUS; GENE TRANSFER; GENETIC ENGINEERING; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOLOGIC MALIGNANCY; HEMATOPOIESIS; HUMAN; LEUKEMIA; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TISSUE DISTRIBUTION;

EID: 7744220566     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2004.05.008     Document Type: Article

References (67)

1. Storb R. Allogeneic hematopoietic stem cell transplantation-yesterday, today and tomorrow Exp Hematol 31 2003 1-10
2. Sullivan K.M. Weiden P.L. Storb R. et al. Influence of acute and chronic graft-vs.-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia Blood 73 1989 1720-1728
3. Suciu S. Mandelli F. de Witte t. et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): An intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial Blood 102 2003 1232-1240
4. Apperley J.F. Jones L. Hale g. et al. Bone marrow transplantation for patients with chronic myeloid leukaemia: T-cell depletion with Campath-1 reduces the incidence of graft-vs.-host disease but may increase the risk of leukaemic relapse Bone Marrow Transplant 1 1986 53-56
5. Hale G. Cobbold S. Waldmann H. T cell depletion with CAMPATH-1 in allogeneic bone marrow transplantation Transplantation 45 1988 753-759
6. Marmont A.M. Horowitz M.M. Gale R.P. et al. T-cell deletion of HLA-identical transplants in leukemia Blood 78 1991 2120-2130
7. Fefer A. Sullivan K.M. Weiden P. et al. Graft vs leukaemia effect in man: The relapse rate of acute leukemia is lower after allogeneic than after syngeneic marrow transplantation Prog Clin Biol Res 244 1987 401-408
8. Ringden O. Labopin M. Gorin N.C. et al. Is there a graft-vs.-leukemia effect in the absence of graft-vs.-host disease in patients undergoing bone marrow transplantation for acute leukaemia? Br J Haematol 111 2000 1130-1137
9. Kolb H.J. Mittermuller J. Clemm C. et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients Blood 76 1990 2462-2465
10. Porter D.L. Roth M.S. McGarigle C. et al. Induction of graft-vs.-host disease as immunotherapy for relapsed chronic myeloid leukemia N Engl J Med 330 1994 100-106
11. Collins R.H. Shpilberg O. Drobyski W.R. et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation J Clin Oncol 15 1997 433-444
12. Kolb H.J. Schattenberg A. Goldman J.M. et al. Graft-vs.-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukaemia Blood 86 1995 2041-2050
13. Levine J.E. Braun T. Penza S.L. et al. Prospective trial of chemotherapy and donor leukocyte infusions for relapse ad advanced myeloid malignancies after allogeneic stem cell transplantation J Clin Oncol 20 2002 405-412
14. Goulmy E. Human minor histocompatibility antigens: New concepts for marrow transplantation and adoptive immunotherapy Immunol Rev 157 1997 125-140
15. Simpson E. Scott D. James E. et al. Minor H antigens: Genes and peptides Transplant Immunol 10 2002 115-123
16. Van den Eynde B.J. Morel S. Differential processing of class-I-restricted epitopes by the standard proteasome and the immunoproteasome Curr Opin Immunol 13 2001 147-153
17. Goldberg A.L. Cascio P. Saric T. et al. The importance of the proteasome and subsequent proteolytic steps in the generation of antigenic peptides Mol Immunol 39 2002 147-164
18. Wang W. Meadows L.R. den Haan J.M. et al. Human H-Y: A male-specific histocompatibility antigen derived from the SMCY protein Science 269 1995 1588-1590
19. Vogt M.H. de Paus R.A. Voogt P.J. et al. DFFRY codes for a new human male-specific minor transplantation antigen involved in bone marrow graft rejection Blood 95 2000 1100-1105
20. Vogt M.H. Goulmy E. Kloosterboer F.M. et al. UTY gene codes for an HLA-B60-restricted human male-specific minor histocompatibility antigen involved in stem cell graft rejection: Characterization of the critical polymorphic amino acid residues for T-cell recognition Blood 96 2000 3126-3132
21. Warren E.H. Gavin M.A. Simpson E. et al. The human UTY gene encodes a novel HLA-B8-restricted H-Y antigen J Immunol 164 2000 2807-2814
22. den Haan J.M. Meadows L.M. Wang W. The minor histocompatibility antigen HA-1: A diallelic gene with a single amino acid polymorphism Science 279 1998 1054-1057
23. Akatsuka Y. Nishida T. Kondo E. et al. Identification of a polymorphic gene, BCL2A1, encoding two novel hematopoietic lineage-specific minor histocompatibility antigens J Exp Med 197 2003 1-13
24. den Haan J.M. Sherman N.E. Blokland E. et al. Identification of a graft vs host disease-associated human minor histocompatibility antigen Science 268 1995 1476-1480
25. Pierce R.A. Field E.D. Mutis T. et al. The HA-2 minor histocompatibility antigen is derived from a diallelic gene encoding a novel human class I myosin protein J Immunol 167 2001 3223-3230
26. Brickner A.G. Warren E.H. Caldwell J.A. et al. The immunogenicity of a new human minor histocompatibility antigen results from differential antigen processing J Exp Med 193 2001 195-206
27. Spierings E. Brickner A.G. Caldwell J.A. et al. The minor histocompatibility antigen HA-3 arises from differential proteasome-mediated cleavage of the lymphoid blast crisis (Lbc) oncoprotein Blood 102 2003 621-629
28. Murata M. Warren E.H. Riddell S.R. A human minor histocompatibility antigen resulting from differential expression due to a gene deletion J Exp Med 197 2003 1279-1289
29. Vogt M.H.J. van den Muijsenberg J.W. van den Muijsenberg J.W. et al. The DBY gene codes for an HLA-DQ5-restricted human male-specific minor histocompatibility antigen involved in graft-vs.-host disease Blood 99 2002 3027-3032
30. Dolstra H. Fredrix H. Maas F. et al. A human minor histocompatibility antigen specific for B cell acute lymphoblastic leukemia J Exp Med 189 1999 301-308
31. Meadows L. Wang W. den Haan J.M. et al. The HLA-A*0201-restricted H-Y antigen contains a posttranslationally modified cysteine residue that significantly affects T cell recognition Immunity 6 1997 273-281
32. de Bueger M. Bakker A. van Rood J.J. et al. Tissue distribution of human minor histocompatibility antigens. Ubiquitous vs restricted tissue distribution indicates heterogeneity among human cytotoxic T lymphocyte-defined non-MHC antigens J Immunol 149 1992 1788-1794
33. Behar E. Chao N.J. Hiraki D.D. et al. Polymorphism of adhesion molecule CD31 and its role in acute graft-vs.-host disease N Engl J Med 334 1996 286-291
34. Wilke M. Dolstra H. Maas F. et al. Quantification of the HA-1 gene product at the RNA level; relevance for immunotherapy of hematological malignancies Hematol J 4 2003 315-320
35. Dolstra H. Fredrix H. Preijers F. et al. Recognition of a B cell leukemia-associated minor histocompatibility antigen by CTL J Immunol 158 1997 560-565
36. Warren E.H. Gavin M. Xuereb S.M. A single nucleotide polymorphism in the SP110 nuclear phosphoprotein gene creates a minor histocompatibility antigen whose expression is regulated by interferon-gamma Blood 98 2002 265
37. Gratwohl A. Hermans J. Niederwieser D. et al. Female donors influence transplant-related mortality and relapse incidence in male recipients of sibling blood and marrow transplants Hematol J 2 2001 336-370
38. Randolph S.S. Gooley T.A. Warren E.H. et al. Female donors contribute to a selective graft-vs.-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants Blood 103 2004 347-352
39. Glucksberg H. Storb R. Fefer A. Clinical manifestations of graft-vs.-host disease in human recipients of marrow from HL-A-matched sibling donors Transplantation 18 1974 295-304
40. Schlomschik W.D. Couzens M.S. Tang C.B. et al. Prevention of graft vs host disease by inactivation of host antigen-presenting cells Science 255 1999 412-415
41. Teshima T. Ordemann R. Reddy P. et al. Acute graft-vs.-host disease does not require alloantigen expression on host epithelium Nat Med 8 2002 575-581
42. Teshima T. Ferrara J.L. Understanding the alloresponse: New approaches to graft-vs.-host disease prevention Semin Hematol 39 2002 15-22
43. Dickinson A.M. Wang X.N. Sviland L. In situ dissection of the graft-vs.-host activities of cytotoxic T cells specific for minor histocompatibility antigens Nat Med 8 2002 410-414
44. Goulmy E. Schipper R. Pool J. et al. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-vs.-host disease after bone marrow transplantation N Engl J Med 334 1996 281-285
45. Mutis T. Gillespie G. Schrama E. et al. Tetrameric HLA class I-minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-vs.-host disease Nat Med 5 1999 839-842
46. Molldrem J.J. Lee P.P. Wang C. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia Nat Med 6 2000 1018-1023
47. Molldrem J. Kant S. Lu S. et al. Peptide vaccination with PR1 elicits active T cell immunity that induces cytogenetic remission in acute myelogenous leukemia Blood 98 2002 8
48. Gale R.P. Horowitz M.M. Ash R.C. et al. Identical-twin bone marrow transplants for leukemia Ann Intern Med 120 1994 646-652
49. Mackinnon S. Papadopoulos E.B. Carabasi M.H. et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-vs.-leukemia responses from graft-vs.-host disease Blood 86 1995 1261-1268
50. Baurmann H. Nagel S. Binder T. et al. Kinetics of the graft-vs.-leukemia response after donor leukocyte infusions for relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation Blood 92 1998 3582-3590
51. Dazzi F. Szydlo R.M. Craddock C. et al. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia Blood 95 2000 67-71
52. Marijt W.A. Heemskerk M.H. Kloosterboer F.M. et al. Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia Proc Natl Acad Sci USA 100 2003 2742-2747
53. Falkenburg J.H.F. Goselink H.M. van der Harst D. et al. Growth inhibition of clonogenic leukaemic precursor cells by minor histocompatibility antigen-specific cytotoxic T lymphocytes J Exp Med 174 1991 27-33
54. Bonnet D. Warren E.H. Greenberg P.D. et al. CD8(+) minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells Proc Natl Acad Sci USA 96 1999 8639-8644
55. Smit W.M. Rijnbeek M. van Bergen C.A. et al. Generation of dendritic cells expressing bcr-abl from CD34-positive chronic myeloid leukemia precursor cells Hum Immunol 53 1997 216-223
56. Choudhury A. Gajewski J.L. Liang J.C. et al. Use of leukaemic dendritic cells for the generation of antileukemic cellular cytoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia Blood 89 1997 1133-1142
57. Brouwer R.E. van der Hoorn M. Kluin-Nelemans H.C. et al. The generation of dendritic-like cells with increased allostimulatory function from acute myeloid leukemia cells of various FAB subclasses Hum Immunol 61 2000 565-574
58. Brouwer R.E. Zwinderman K.H. Kluin-Nelemans H.C. et al. Expression and induction of costimulatory and adhesion molecules on acute myeloid leukaemic cells: Implications for adoptive immunotherapy Exp Hematol 28 2000 161-168
59. Heslop H.E. Ng C.Y. Li C. et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes Nat Med 2 1996 55-555
60. Riddell S.R. Watanabe K.S. Goodrich J.M. et al. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones Science 257 1992 238-241
61. Falkenburg J.H.F. Wafelman A.R. Joosten P. et al. Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes Blood 94 1999 1201-1208
62. Warren E.H. Kelly D.M. Brown M.L. et al. Adoptive GVL therapy targeting minor histocompatibility antigens for the treatment of posttransplant leukemic relapse-update of the FHCRC experience Blood 98 2002 2493
63. Mutis T. Verdijk R. Schrama E. et al. Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens Blood 94 1999 2336-2341
64. Heemskerk M.H. Hoogeboom M. de Paus R.A. et al. Redirection of antileukemic reactivity of peripheral T lymphocytes using gene transfer of minor histocompatibility antigen HA-2-specific T-cell receptor complexes expressing a conserved alpha joining region Blood 102 2003 3530-3540
65. Heemskerk M.H. Hoogeboom M. Hagedoorn R. et al. Reprogramming of virus specific T cells into leukemia-reactive T cells using T cell receptor gene transfer J Exp Med 199 2004 885-894
66. Kessels H.W. Wolkers M.C. van den Boom M.D. et al. Immunotherapy through TCR gene transfer Nat Immunol 2 2001 957-961
67. Bonini C. Grez M. Traversari C. et al. Safety of retroviral gene marking with a truncated NGF receptor Nat Med 9 2003 367-369